期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 8, 期 1, 页码 33-42出版社
EXPERT REVIEWS
DOI: 10.1586/14737140.8.1.33
关键词
ETS factor; gene fusion; metastasis; oncogene; prostate cancer; therapeutic target; transcription; tumor suppressor
类别
资金
- NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER
- NCI NIH HHS [P01 CA78582] Funding Source: Medline
ETS factors represent one of the largest families of transcriptional regulators and have known functional roles in many biological processes. Significantly, ETS factors have oncogenic and suppressive activity and their aberrant expression is associated with many of the processes that lead to prostate cancer progression. The targeting of transcription for therapeutic gain has met with some success. Therefore, better understanding the mechanisms that regulate ETS factor activity during both normal and aberrant transcription provides a novel means to identify processes that may be targeted in order to re-establish the normal ETS regulatory networks that are perturbed in cancer. Specific examples of altered ETS factor expression are highlighted, and therapeutic technologies that may be used to target ETS factors and their cofactors and downstream target genes in prostate cancer are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据